ASH Conference Highlights
A maintenance regimen of lenalidomide (Revli-mid) and elotuzumab (Empliciti) after autologous stem cell transplant (ASCT) improved the quality of responses achieved with induction therapy in patients with multiple myeloma.
CAR T-Cell Therapy Targeting B-Cell Maturation Antigen Shows “Impressive” Results in Multiple Myeloma
Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma.
A retrospective analysis of a large commercial payer database has demonstrated a link between various treatment episodes of acute myeloid leukemia (AML) and substantial economic burden.
Venetoclax (Venclexta) plus rituximab (Rituxan) achieved superior progression-free survival (PFS) and overall survival (OS) compared with standard-of-care bendamustine (Treanda/Bendeka) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Sotatercept, a First-in-Class Agent, Improves Hemoglobin Levels in Anemic Patients with Myelofibrosis
Sotatercept, an investigational activin receptor IIA ligand trap, when used alone or in combination with ruxolitinib (Jakafi), safely increases hemoglobin levels in patients with myeloproliferative neoplasm–associated myelofibrosis, according to data from a phase 2, investigator-initiated clinical trial.
Although there have been major advancements in the treatment of hematologic malignancies in recent years, according to Richard Pazdur, MD, Director, FDA’s Oncology Center of Excellence, the number of agents approved in 2017 for acute myeloid leukemia (AML) was nothing short of “phenomenal.”
Which Combination Immunotherapies to Use, and When? Despite Improved Response Rates, Serious Toxicity Remains a Concern
As single-agent immunotherapies continue to show promising results, the challenge is now to determine which combination regimens with immunotherapies can improve outcomes.
Direct oral anticoagulants (DOACs) may replace low molecular weight heparin (LMWH) as standard of care for management of venous thromboembolism (VTE) in cancer patients, judging by the results of 2 randomized trials presented at ASH 2017.
CAR T-Cell Therapy Makes Significant Inroads in Lymphoma: Kymriah and Yescarta Show Durable Remissions
CD19-directed chimeric antigen receptor (CAR) T-cell therapy continues to show excellent and durable responses in patients with lymphoma who have no other treatment options.
Results 1 - 9 of 9